Study of Two Oral Vapendavir Doses Versus Placebo for Treating Rhinovirus in Adults with COPD

What this Trial Is About

Researchers are evaluating the safety and effectiveness of two different oral doses of vapendavir VPV compared to a placebo in adults aged 40 to 85 years who have chronic obstructive pulmonary disease COPD and rhinovirus infections. The goal is to determine the appropriate dose of VPV to reduce the severity and duration of respiratory symptoms caused by these infections. This is a Phase 2, randomized, double-blind clinical trial sponsored by Altesa Biosciences, Inc. Participants are randomly assigned to one of three groups VPV 1000 mg, VPV 500 mg, or placebo. The first dose is taken at the study site with food, followed by a second dose taken at home the next morning with food. Subsequent doses are taken every 24 hours with food for a total of 7 doses. The study uses a parallel design to compare these groups over the treatment period. During the study, participants will complete daily assessments of respiratory symptoms using the Evaluating Respiratory Symptoms E-RS tool for up to 42 days following a 12-week baseline period. Additional measurements include lung function tests, oscillometry assessments, patient global impressions, and symptom surveys at specific time points throughout the study. Safety and efficacy are closely monitored, with participants followed until the study ends in November 2027.

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD